<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03782051</url>
  </required_header>
  <id_info>
    <org_study_id>1102108</org_study_id>
    <nct_id>NCT03782051</nct_id>
  </id_info>
  <brief_title>Combined Viscocanalostomy, Phacoemulsification, OIogen Implant in Open Angle Glaucoma</brief_title>
  <acronym>Visco-ologen</acronym>
  <official_title>Combined Phacoemulsification and Viscocanalostomy With Ologen Implant Versus Combined Phacoemulsification and Viscocanalostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, interventional, randomized clinical study was done at Alpha Vision Center,
      Zagazig, Egypt. Patients with coexisting cataract and glaucoma were randomized to receive
      either phaco-viscocanalostomy (Phacovisco group) or phaco-viscocanalostomy with Ologen®
      implant (OloPhacovisco group) . Follow-up period was 2 years. Nd:YAG laser goniopuncture was
      done in cases where the intraocular pressure (IOP) was elevated above 21 mmHg after
      discontinuation of corticosteroid eye drops at any follow-up visit.

      Our hypothesis is that using Ologen® implant as a spacer in the subscleral reservoir in
      phaco-viscocanalostomy reduces fibrosis and increase the success rate of this operation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: To study the efficacy of the biodegradable collagen implant Ologen® as an
      adjuvant in phaco-viscocanalostomy in patients with coexisting cataract and primary open
      angle glaucoma.

      Methods: This prospective, interventional, randomized clinical study was done at Alpha Vision
      Center, Zagazig, Egypt. Patients with coexisting cataract and glaucoma were randomized to
      receive either phaco-viscocanalostomy (Phacovisco group) or phaco-viscocanalostomy with
      Ologen® implant (OloPhacovisco group). Follow-up period was 2 years. Nd:YAG laser
      goniopuncture was done in cases where the intraocular pressure (IOP) was elevated above 21
      mmHg after discontinuation of corticosteroid eye drops at any follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2013</start_date>
  <completion_date type="Actual">January 14, 2018</completion_date>
  <primary_completion_date type="Actual">January 14, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the intraocular pressure</measure>
    <time_frame>2 years</time_frame>
    <description>measured by mmHg using Goldman applanatin tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgical complications</measure>
    <time_frame>2 years</time_frame>
    <description>number of surgical complications encountered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the use and results of Nd:YAG laser goniopuncture</measure>
    <time_frame>2 years</time_frame>
    <description>number of cases needed goniopuncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity results</measure>
    <time_frame>2 years</time_frame>
    <description>visual acuity measured by decimal system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Phacovisco group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group had combined phacoemulsification and viscocanalostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OloPhacovisco group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group had combined phacoemulsification and viscocanalostomy and Ologen</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>combined phacoemulsification and viscocanalostomy</intervention_name>
    <description>phacoemulsification with viscocanalostomy</description>
    <arm_group_label>Phacovisco group</arm_group_label>
    <other_name>phaco-visco-canalostomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>combined phacoemulsification and viscocanalostomy and ologen</intervention_name>
    <description>phacoemulsification with viscocanalostomy with ologen</description>
    <arm_group_label>OloPhacovisco group</arm_group_label>
    <other_name>phaco-visco-canalostomy with ologen implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the presence of significant cataract interfering with vision (visual acuity ≤ 0.5) in
             the presence POAG.

          -  if cataract was associated with uncontrolled glaucoma, (IOP &gt; 21 mmHg despite
             maximally tolerated medical therapy)

          -  if the IOP was ≤ 21 mmHg with use of at least two antiglaucoma drugs with medication
             intolerance

          -  poor patient compliance

          -  patients could not attend medical supervision

          -  patients had visual field deterioration.

        Exclusion Criteria:

          -  closed-angle glaucoma

          -  other types of open angle glaucoma (OAG), e.g. pigmentary glaucoma, inflammatory
             glaucoma or neovascular glaucoma,

          -  previous ocular trauma or surgery

          -  lens subluxation

          -  any eye diseases affecting the vision, e.g. anterior uveitis

          -  if there was a large perforation of the Descemet's membrane with iris prolapse during
             surgery (cases with microperforation, which is defined as small perforation with no
             associated iris prolapse, occurring during surgery were not excluded) intraoperative
             complications that might affect the IOP, e.g. vitreous loss.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed AM Gad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zagazig University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alpha vision center</name>
      <address>
        <city>Zagazig</city>
        <state>Al Sharkeya</state>
        <zip>44511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Cillino S, Di Pace F, Cillino G, Casuccio A. Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial. Eye (Lond). 2011 Dec;25(12):1598-606. doi: 10.1038/eye.2011.219. Epub 2011 Sep 16.</citation>
    <PMID>21921953</PMID>
  </reference>
  <reference>
    <citation>Narayanaswamy A, Perera SA, Htoon HM, Hoh ST, Seah SK, Wong TT, Aung T. Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year. Clin Exp Ophthalmol. 2013 Aug;41(6):552-60. doi: 10.1111/ceo.12058.</citation>
    <PMID>23279607</PMID>
  </reference>
  <reference>
    <citation>Johnson MS, Sarkisian SR Jr. Using a collagen matrix implant (Ologen) versus mitomycin-C as a wound healing modulator in trabeculectomy with the Ex-PRESS mini glaucoma device: a 12-month retrospective review. J Glaucoma. 2014 Dec;23(9):649-52. doi: 10.1097/IJG.0000000000000018.</citation>
    <PMID>24240882</PMID>
  </reference>
  <reference>
    <citation>Hondur A, Onol M, Hasanreisoglu B. Nonpenetrating glaucoma surgery: meta-analysis of recent results. J Glaucoma. 2008 Mar;17(2):139-46. doi: 10.1097/IJG.0b013e31814b98f7.</citation>
    <PMID>18344761</PMID>
  </reference>
  <reference>
    <citation>Shaarawy T, Mermoud A. Deep sclerectomy in one eye vs deep sclerectomy with collagen implant in the contralateral eye of the same patient: long-term follow-up. Eye (Lond). 2005 Mar;19(3):298-302.</citation>
    <PMID>15258610</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 16, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Ahmed moamen</investigator_full_name>
    <investigator_title>princibal investigator, lecturer of ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Viscocanalostomy</keyword>
  <keyword>Ologen</keyword>
  <keyword>glaucoma</keyword>
  <keyword>phacoemulsification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT03782051/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

